HIV-HCV Co-Infection among Multitransfused Thalassemic Individuals-A Review

Biswas, Aritra; Gupta, Debanjali; Ghosh, Monika; Datta, Abira; Gupta, Nabyendu; Firdaus, Rushna; Sadhukhan, Provash Chandra

doi:10.15406/jhvrv.2016.03.00103

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coinfection is consequently common in people with high exposure to blood and blood products. 32 The primary concern of coinfection is that it can lead to more severe liver diseases in multitransfused patients. 6 NAT testing was introduced in the developed countries in the late 1990s and early 2000s and presently, around 33 countries in the world have implemented NAT for HIV; 33,34 however, NAT is not as yet a mandatory screening test in India.…”

Section: Hepatitis C Virus (Hcvmentioning

confidence: 99%

“…6 There are several reports related to HIV/HCV coinfection among thalassemic patients; however there is no report related to HBV/HCV coinfection that can lead to liver cirrhosis and hepatocellular carcinoma (HCC), and no report related to HIV/HBV from different parts of India. 7,8 Blood units are screened with assays of steadily increasing sensitivity for Hepatitis-B surface antigen (HBsAg) since 1971, against HIV since 1989 and against HCV since 2001. 9 Indeed, the risk of being infected by a contaminated blood unit today is orders of magnitude lower when compared to thirty years ago, due to continuous improvement and implementation of donor selection, sensitive screening tests.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Seroprevalence of Hbv, HCV and Hiv-1 and Correlation With Molecular Markers Among Multi-Transfused Thalassemia Patients in Western India

Mishra¹,

Shah²,

Patel³

et al. 2020

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Background: Blood transfusion is a lifesaving therapy for patients with hemoglobinopathies. However, the need of frequent transfusion carries the risk of transfusion-transmitted infections (TTIs). This study was aimed to determine the seroprevalence of Hep-B, Hep-C and HIV-1infections among the multi-transfused Beta-thalassemic patients and correlate the same with NAT testing. Methods: Total 196 patients with Beta-thalassemia were included in the study. Patients were screened for the presence of viral markers by third generation ELISA test as well as for viral DNA/RNA by NAT. Results: Among these 196 multi-transfused Beta-thalassemia patients, 32.1% were females and 67.8% were males. A total of 100 (51.1%) patients were found to be anti-HCV antibody reactive, while HCV-RNA was positive in 66 (33.7 %) of the 196 patients tested. There were 6 (3.1%) patients reactive for anti-HIV-1 antibody, while 8 (4.1%) were positive for HIV-RNA. There were only 3 (1.5%) patients that were found to be reactive for HBsAg, however 5 (2.5%) were positive for HBV-DNA. Two (1%) patients had co-infection of anti-HCV antibody and HBsAg,whereas 6 patients were found co-infected by NAT testing, in-which 3 (1.5%) were positive for HBV-DNA and HCV-RNA, 1 (0.5%) was positive for HIV-RNA and HBV-DNA, and 2 (1%) had co-infection of HIV-RNA and HCV RNA. Conclusion: Prevalence of HCV among multi-transfused Beta-thalassemia patients is significantly higher than the normal population. On the other hand, the study showed low prevalence of HBV. Therefore, a follow-up schedule and administration of booster dose of HBV vaccine is strongly recommended for thalassemia patients. To the best of our knowledge, this is the foremost work that shows prevalence of HIV, HBV and HCV in thalassemia patients using both serology and molecular markers in Western India.

show abstract

Section: Hepatitis C Virus (Hcvmentioning

confidence: 99%

mentioning

confidence: 99%